Senior health advisor for Esri
VP of Research & Policy, Ewing Marion Kauffman Foundation
Co-Founder and CEO, Wetpaint
Chair, Department of Chemical Physiology, The Scripps Research Institute; Co-director, Center for Physiological Proteomics, The Scripps Research Institute
Dendreon, the Seattle-based developer of an immune-boosting treatment for prostate cancer, is holding its annual shareholders meeting at its headquarters in Belltown. Shareholders are being asked to elect two new members to the company’s 12-member board of directors, and give the company (NASDAQ: DNDN) the ability to sell another 100 million shares of stock if it chooses.